Latest Lumos Diagnostics (ASX:LDX) News

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.

Lumos Diagnostics Holdings Limited (ASX: LDX) has opened a Share Purchase Plan (SPP) offering eligible shareholders the chance to invest up to A$30,000 at A$0.225 per share, accompanied by free options. The SPP aims to raise up to A$2 million and closes on 24 April 2026.

Lumos Diagnostics has entered a three-year contract manufacturing agreement with Micro-Pak to produce the Mold Analyzer system, marking a transition from development to commercial-scale manufacturing with an initial US$250,000 purchase order.

Critical minerals stole the spotlight as big project numbers, new processing results and fresh funding pushed several small caps sharply higher. A few capital raisings and legal headlines also hit hard, especially where early gains couldn’t hold.

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Micro-caps stole the spotlight, led by a boardroom reset at Killi and a blockbuster cancer update from Amplia. Energy explorers and a few big raisings moved the other way, as traders sold hard into fresh dilution and weak price action.

Cancer drug data and two separate Mayo Clinic-linked deals drove the biggest moves this week. Investors paid up for clearer routes to hospital rollouts, while one digital screening name fell hard after early gains evaporated.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.